Cargando…

Tracking Japan’s development assistance for health, 2012–2016

BACKGROUND: Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomura, Shuhei, Sakamoto, Haruka, Sugai, Maaya Kita, Nakamura, Haruyo, Maruyama-Sakurai, Keiko, Lee, Sangnim, Ishizuka, Aya, Shibuya, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161223/
https://www.ncbi.nlm.nih.gov/pubmed/32293475
http://dx.doi.org/10.1186/s12992-020-00559-2
_version_ 1783522917181554688
author Nomura, Shuhei
Sakamoto, Haruka
Sugai, Maaya Kita
Nakamura, Haruyo
Maruyama-Sakurai, Keiko
Lee, Sangnim
Ishizuka, Aya
Shibuya, Kenji
author_facet Nomura, Shuhei
Sakamoto, Haruka
Sugai, Maaya Kita
Nakamura, Haruyo
Maruyama-Sakurai, Keiko
Lee, Sangnim
Ishizuka, Aya
Shibuya, Kenji
author_sort Nomura, Shuhei
collection PubMed
description BACKGROUND: Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarified its flows, including source, aid type, channel, target region, and target health focus area. METHODS: Data on Japan Tracker, the first data platform of Japan’s DAH, were used. The DAH definition was based on the Organisation for Economic Co-operation and Development’s (OECD) sector classification. Regarding core funding to non-health-specific multilateral agencies, we estimated DAH and its flows based on the OECD methodology for calculating imputed multilateral official development assistance (ODA). RESULTS: Japan’s DAH was estimated at 1472.94 (2012), 823.15 (2013), 832.06 (2014), 701.98 (2015), and 894.57 million USD (2016) in constant prices of 2016. Multilateral agencies received the largest DAH share of 44.96–57.01% in these periods, followed by bilateral grants (34.59–53.08%) and bilateral loans (1.96–15.04%). Ministry of Foreign Affairs (MOFA) was the largest contributors to the DAH (76.26–82.68%), followed by Ministry of Finance (MOF) (10.86–16.25%). Japan’s DAH was most heavily distributed in the African region with 41.64–53.48% share. The channel through which the most DAH went was Global Fund to Fight AIDS, Tuberculosis, and Malaria (20.04–34.89%). Between 2012 and 2016, approximately 70% was allocated to primary health care and the rest to health system strengthening. CONCLUSIONS: With many major high-level health related meetings ahead, coming years will play a powerful opportunity to reevaluate DAH and shape the future of DAH for Japan. We hope that the results of this study will enhance the social debate for and contribute to the implementation of Japan’s DAH with a more efficient and effective strategy.
format Online
Article
Text
id pubmed-7161223
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71612232020-04-22 Tracking Japan’s development assistance for health, 2012–2016 Nomura, Shuhei Sakamoto, Haruka Sugai, Maaya Kita Nakamura, Haruyo Maruyama-Sakurai, Keiko Lee, Sangnim Ishizuka, Aya Shibuya, Kenji Global Health Research BACKGROUND: Development assistance for health (DAH) is one of the most important means for Japan to promote diplomacy with developing countries and contribute to the international community. This study, for the first time, estimated the gross disbursement of Japan’s DAH from 2012 to 2016 and clarified its flows, including source, aid type, channel, target region, and target health focus area. METHODS: Data on Japan Tracker, the first data platform of Japan’s DAH, were used. The DAH definition was based on the Organisation for Economic Co-operation and Development’s (OECD) sector classification. Regarding core funding to non-health-specific multilateral agencies, we estimated DAH and its flows based on the OECD methodology for calculating imputed multilateral official development assistance (ODA). RESULTS: Japan’s DAH was estimated at 1472.94 (2012), 823.15 (2013), 832.06 (2014), 701.98 (2015), and 894.57 million USD (2016) in constant prices of 2016. Multilateral agencies received the largest DAH share of 44.96–57.01% in these periods, followed by bilateral grants (34.59–53.08%) and bilateral loans (1.96–15.04%). Ministry of Foreign Affairs (MOFA) was the largest contributors to the DAH (76.26–82.68%), followed by Ministry of Finance (MOF) (10.86–16.25%). Japan’s DAH was most heavily distributed in the African region with 41.64–53.48% share. The channel through which the most DAH went was Global Fund to Fight AIDS, Tuberculosis, and Malaria (20.04–34.89%). Between 2012 and 2016, approximately 70% was allocated to primary health care and the rest to health system strengthening. CONCLUSIONS: With many major high-level health related meetings ahead, coming years will play a powerful opportunity to reevaluate DAH and shape the future of DAH for Japan. We hope that the results of this study will enhance the social debate for and contribute to the implementation of Japan’s DAH with a more efficient and effective strategy. BioMed Central 2020-04-15 /pmc/articles/PMC7161223/ /pubmed/32293475 http://dx.doi.org/10.1186/s12992-020-00559-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nomura, Shuhei
Sakamoto, Haruka
Sugai, Maaya Kita
Nakamura, Haruyo
Maruyama-Sakurai, Keiko
Lee, Sangnim
Ishizuka, Aya
Shibuya, Kenji
Tracking Japan’s development assistance for health, 2012–2016
title Tracking Japan’s development assistance for health, 2012–2016
title_full Tracking Japan’s development assistance for health, 2012–2016
title_fullStr Tracking Japan’s development assistance for health, 2012–2016
title_full_unstemmed Tracking Japan’s development assistance for health, 2012–2016
title_short Tracking Japan’s development assistance for health, 2012–2016
title_sort tracking japan’s development assistance for health, 2012–2016
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161223/
https://www.ncbi.nlm.nih.gov/pubmed/32293475
http://dx.doi.org/10.1186/s12992-020-00559-2
work_keys_str_mv AT nomurashuhei trackingjapansdevelopmentassistanceforhealth20122016
AT sakamotoharuka trackingjapansdevelopmentassistanceforhealth20122016
AT sugaimaayakita trackingjapansdevelopmentassistanceforhealth20122016
AT nakamuraharuyo trackingjapansdevelopmentassistanceforhealth20122016
AT maruyamasakuraikeiko trackingjapansdevelopmentassistanceforhealth20122016
AT leesangnim trackingjapansdevelopmentassistanceforhealth20122016
AT ishizukaaya trackingjapansdevelopmentassistanceforhealth20122016
AT shibuyakenji trackingjapansdevelopmentassistanceforhealth20122016